TMS for Adults With Autism and Depression

Not Applicable

Completed

• Conditions: Depression; Depressive Disorder; Major Depressive Disorder; Autism Spectrum Disorder
• Interventions: Device: NeuroStar® TMS device (Neuronetics, Atlanta, GA)

• Registration Number: NCT02939560
• Lead Sponsor: Medical University of South Carolina

Brief Summary

The goal of this proposal is to investigate whether a standard rTMS protocol for depression, including multiple sessions applied to left dorsolateral prefrontal cortex (DLPFC) results in reduction of depressive symptoms for adult patients with ASD and MDD (Aim 1). The secondary goal is to investigate and whether there is any beneficial reduction in the core symptoms of autism (Aim 2).

Detailed Description

Aim 1. Determine the safety and therapeutic efficacy of left-sided DLPFC high frequency rTMS on MDD symptoms in patients with ASD: The investigators hypothesize that patients receiving the rTMS will tolerate the treatment course without difficulty and have clinically significant reduction of depressive symptoms after receiving all 25 sessions, as compared with their symptom burden prior to initiating TMS. Depression symptom data will be collected as pre- and post-TMS scores on Hamilton Depression Rating Scale (HAM-D). Depression scores will also be monitored periodically during course of TMS with Patient Health Questionnaires (PHQ-9).

Exploratory sub-aim - Monitoring for durability of response: The investigators hypothesize that subjects receiving rTMS will demonstrate durability of response in their depression symptom reduction, as measured by HAM-D scores at 1 month and 3 months post-TMS.

Aim 2. Determine the effect of left DLPFC rTMS on core symptoms of ASD: The investigators hypothesize that subjects will experience reduction in core symptoms of ASD after completing all 25 sessions, as compared with their symptom burden prior to initiating treatment. For social and communication deficits, informant and/or self-report evaluations will be made pre- and post-TMS with the Social Responsiveness Scale (SRS), the Ritvo Autism Aspergers Diagnostic Scale-Revised (RAADS-R) and the Aberrant Behavior Checklist (ABC). Repetitive and restricted behavior will be evaluated using the Repetitive Behavior Scale-Revised (RBS-R), the ABC, and RAADS.

Exploratory sub-aim: Determine if there are changes to functional brain connectivity during face and object processing tasks via functional MRI imaging in patients with Autism who receive rTMS: The study investigators hypothesize that there will be altered brain connectivity evident in patients' baseline fMRI during cognitive processing tasks prior to TMS reflected as both hyper- and hypo-connectivity, and that there will be some level of normalization of these patterns in fMRI after completion of TMS series, particularly in the prefrontal cortex.

Exploratory sub-aim - Monitoring for durability of response: The study investigators hypothesize that subjects receiving rTMS will exhibit durability of response in their ASD symptom reduction, as measured by ABC, SRS, RAADS, AND RBR scores at 1 month and 3 months post-TMS.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2016-09
• Study First Submitted: 2016-09-29
• Study First Submitted QC: 2016-10-18
• Study First Posted: 2016-10-20
• Primary Completion: 2018-06-01
• Study Completion: 2018-09-20
• Results First Submitted: 2019-06-24
• Status Verified: 2019-09
• Results First Submitted QC: 2019-09-10
• Last Update Submitted: 2019-09-10
• Results First Posted: 2019-10-01
• Last Update Posted: 2019-10-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

• Diagnosis of Autism Spectrum Disorder and active depressive symptoms.

Read More

Exclusion Criteria

• List specific contraindicationsUncontrolled and/or untreated seizure disorder as defined by any incidence of seizure within the past 6 months. Patients with diagnosed epilepsy, or prior seizures, will be allowed in the study if they are taking an anticonvulsant medication, or have not had a seizure in the past year off medications.

• Moderate to severe intellectual disability (ID) as defined by IQ < 60, determined by prior IQ testing or Wechsler Abbreviated Scale of Intelligence (WASC-II) if no prior test results available

• Other psychiatric or neurodevelopmental illness that is the primary area of clinical focus (including but not limited to primary psychotic disorder, substance abuse disorder, and ASD or ID which are secondary to genetic syndromes)

• Active suicidal ideation or suicide attempt in the 90 days prior to initial assessment

• Presence of any metal implants or devices in the head or neck (e.g. metal plates or screws)

• No participants who are pregnant or who are planning to become pregnant

• Exclusion criteria for fMRI scanning:

  • have metal pins, plates or clips in the body or have orthodontics
  • have surgical implants such as pacemakers or cochlear implants
  • have permanent makeup or tattoos near the face or head
  • have metal fragments in the body (from welding, shrapnel, BB guns) or suspect that they have fragments
  • are claustrophobic
  • are pregnant
  • have ever suffered a closed head injury or concussion
  • are currently under the influence of alcohol or other recreational drugs
  • are a smoker
  • are currently enrolled in a course in which the PI or co-I's are instructors
  • cannot understand the task instructions
  • cannot lay still in the mock scanner for a period of 6 minutes

• Inability or unwillingness of participant or legal guardian/representative to give informed consent

• There will be no discrimination or exclusions based on race, gender, sexual orientation, or other socioeconomic factors. Of note, while both male and female participants will be actively and equally recruited using the same methods. The natural distribution of autism in the population skews towards significant towards male gender, with male prevalence being 4-5 times that of female prevalence. Our study will therefore likely have more male participants than female due to this trend in prevalence.

• Children (age <18) are being excluded from this study for several reasons. While autism is a pediatric neurodevelopmental disorder with symptom onset as young as one year of age, it is also one that is chronic throughout adulthood. Both children with autism and neurotypical children undergo periods of rapid change in brain size, structure, and organization as they age, and the interaction between a full rTMS series and brains that are still involved in periods of very active development and whom may also be at different points along their own developmental timelines may skew or alter the data that is collected. Additionally, due to both brain growth and increases in skull thickness, children of different ages may have significantly different "scalp to cortex" distances, which can result in very different patterns of cortical stimulation despite uniform coil positioning. This will be an added, unnecessary variable which would compromise the attempt at performing a standardized protocol. Finally, while high frequency rTMS is an FDA approved treatment for depression in adults, it has not yet been FDA approved in children and adolescents.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
rTMS	NeuroStar® TMS device (Neuronetics, Atlanta, GA)	Participants will receive rTMS sessions according to the study protocol.

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Aberrant Behavior Checklist	Baseline, Week 5, Week 9, Week 17	Aberrant Behavior Checklist. Minimum 0, maximum 174. Higher scores indicate worse behaviors.
Change From Baseline in Social Responsiveness Scale-2	Baseline, Week 5, Week 9, Week 17	Social Responsiveness Scale-2. Minimum 0, maximum 195. Higher indicates worse behaviors
Change From Baseline in Hamilton Depression Rating Scale	Baseline through Week 5	Hamilton Depression Rating Scale (HAM-D) with 17 questions. Minimum score = 0, maximum 53. Higher scores mean more severe depression.
Change From Baseline in Ritvo Autism-Aspergers Diagnostic Scale	Baseline, Week 5, Week 9, Week 17	Ritvo Autism-Aspergers Diagnostic Scale. Minimum 0, maximum 240. Higher indicates worse symptoms.
Change From Baseline in Repetitive Behavior Scale-Revised	Baseline, Week 5, Week 9, Week 17	Repetitive Behavior Scale-Revised Global Impression. Minimum 0, maximum 100. Higher indicates worse behaviors

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Functional MRI Scanning During Cognitive Processing Tasks	Baseline, Week 5	Functional MRI data during cognitive processing tasks

Trial Locations

Locations (1)

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States